



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY AND MEDICINE  
Volume 15 Issue 2 Version 1.0 Year 2015  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Marijuana: Neurotoxic or Neuroprotective?

By Manoj Banjara

*Texas Tech University Health Sciences Center, United States*

**Abstract-** Chronic marijuana intake was known to induce morphological changes to the brain impairing memory and learning ability. However, several studies demonstrated the protective effect of marijuana post-brain traumas. This article reviews studies that strengthen our horizon to understand the effects of marijuana smoking in brain. This review predicts that optimum use of marijuana or pure marijuana compound can be beneficial or detrimental depending on the consumed dose.

**Keywords:** *marijuana, cannabinoids, neuroprotective, neurotoxic.*

**GJMR-B Classification :** *NLMC Code: QW 630.5.N4*



*Strictly as per the compliance and regulations of:*



# Marijuana: Neurotoxic or Neuroprotective?

Manoj Banjara

**Abstract-** Chronic marijuana intake was known to induce morphological changes to the brain impairing memory and learning ability. However, several studies demonstrated the protective effect of marijuana post-brain traumas. This article reviews studies that strengthen our horizon to understand the effects of marijuana smoking in brain. This review predicts that optimum use of marijuana or pure marijuana compound can be beneficial or detrimental depending on the consumed dose.

**Keywords:** marijuana, cannabinoids, neuroprotective, neurotoxic.

## I. INTRODUCTION

Marijuana is the dried leaves, flowers, stems, and seeds from the plant *Cannabis sativa*. It has several psychoactive chemicals along with a relatively well-characterized delta-9-tetrahydrocannabinol ( $\Delta^9$ -THC). Marijuana can also be concentrated in a resin called hashish or a black sticky liquid called hash oil. It is the most common illicit drug in the United States. Even though federal government considers marijuana as a Schedule I substance, several states have legalized it for medicinal and recreational use ([www.drugabuse.gov](http://www.drugabuse.gov)).

Numerous compounds are produced when marijuana is smoked, which may have acute or chronic effect. G protein-coupled cannabinoid (CB) receptors are involved to respond acute effects of cannabinoids and the development of tolerance. CB1 receptors are predominantly available in the hippocampus, striatum, and cerebellum in the brain (Ameri 1999). Another cannabinoid receptor, CB2, is mostly found in spleen, which has only about 44% nucleotide sequence similarity with CB1 receptor (Ameri 1999).

Even though marijuana is the most common street drug, it has been employed as a therapeutic drug. There are well-proofed potential medicinal actions of marijuana, such as antiemetic, analgesia, anticonvulsant, and lower intraocular pressure (Hollister 1986). However, psychological effects, development of tolerance, and the abuse potential of marijuana have discouraged their medicinal use. In addition, the public debate exists whether or not marijuana should be legalized. Thus, it is the aim of this review to present the effect of marijuana and its psychoactive components on brain and evaluate if it is neuroprotective or neurotoxic.

**Author:** Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX. e-mail: [btsmanoj@gmail.com](mailto:btsmanoj@gmail.com)

## II. NEUROLOGICAL EFFECTS

Although marijuana have shown direct cellular effects on a number of organ systems such as immune system, liver, reproductive system, and digestive system, major behavioral and pharmacological effects involve the central nervous system (CNS) (Ameri 1999). The behavioral effects of marijuana may vary depending on dose and route of administration, expectations of subjects, and individual vulnerability to certain effect. Marijuana at low doses generally produces euphoric, relaxation, and stimulatory effects, and at higher doses they exert predominantly depression (Lukas et al. 1995). Acute marijuana is associated with impaired functioning in cognitive and performance tasks such as reaction time, learning perception, motor coordination and attention (Court 1998; Heishman et al. 1997). Multiple studies have implicated that marijuana deficits short-term memory, which mediate CB1 receptors (Heyser et al. 1993; Lichtman and Martin 1996).

One biological effects of  $\Delta^9$ -THC is their ability of inhibiting pain transmission (Martin et al. 1996), potentially involving neuronal pathway of  $\kappa$  opioid receptors with distal or converging pathway of cannabinoid receptors (Ameri 1999; Calignano et al. 1998).

Multiple studies suggest that marijuana possess antiepileptic properties in animal seizure models and human patients (Carlini and Cunha 1981; Karler and Turkanis 1981). Available evidences predicted the antiepileptic property of marijuana is due to its interaction with the glutamatergic transmission in the central nervous system (Feigenbaum et al. 1989).

## III. MARIJUANA-INDUCED CNS MODIFICATION: NEUROTOXIC OR NEUROPROTECTIVE?

Multiple studies revealed neuroprotective and neurotoxic effects of marijuana in animal models or human systems. It was shown to induce beneficial or detrimental effects at cellular level (Bash et al. 2003; Same and Keren 2004).

Many epidemiological studies have demonstrated that chronic use of marijuana deteriorates cognitive functions, specific impairment of attention, memory, and executive function (Pope and Yurgelun-Todd 1996; Schweinsburg et al. 2008; Solowij et al. 1995). Interestingly, unlike ethanol, cognitive impairment caused by marijuana is not clearly dose-dependent.

However, chronic (at least several months) marijuana exposure may cause long-term impairment (Pope and Yurgelun-Todd 1996). A major psychoactive ingredient of marijuana,  $\Delta^9$ -THC, persistently reduced maze learning ability in rats (Fehr et al. 1976; Stiglick and Kalant 1982; Stiglick et al. 1984). Similar results were detected in rats with hippocampal lesions, suggesting the possibility of neurotoxic effects of marijuana in the hippocampus (Morris et al. 1982). In addition, neuronal death and reduced synaptic density and dendritic length of pyramidal neurons were measured in the hippocampus of chronic marijuana administered rats (Landfield et al. 1988; Lawston et al. 2000). Furthermore, THC induced neuronal death in the neuronal cell lines, cultured hippocampal neurons or hippocampal slices (Chan et al. 1998). Chan et al. presented evidences of  $\Delta^9$ -THC inducing apoptosis of hippocampal neurons by shrinking neuronal bodies and nuclei as well as DNA fragmentation (Chan et al. 1998). Furthermore, the neuronal cell loss is assumed to be responsible for impairment in memory after long-lasting consumption of marijuana. 10 and 1  $\mu$ M THC are found to induce 50% hippocampal neuronal death in 2 hr and 5 days, respectively (Chan et al. 1998). In a separate report, marijuana was considered to produce toxic encephalopathy in young humans (Court 1998).

In contrast to the above reports, marijuana induces the expression of endocannabinoid 2-arachidonoyl glycerol (2-AG), which reduced brain edema and infarct volume following severe closed head injury (Sarne et al. 2011). In addition, CB1 and CB2 receptors agonist Bay 38-7271 demonstrated neuroprotective properties in traumatic brain injury and focal ischemic rat models (Sarne et al. 2011; Sarne and Keren 2004). Additionally, the role of endogenous cannabinoid system is suggested to be neuroprotective (Guzman et al. 2001; Mechoulam et al. 2002). Multiple *in vitro* studies have reported protection of neurons in culture by cannabinoid agonists acting through CB1 receptors (Shen and Thayer 1998). Also, CB1 receptor acting cannabinoid agonists protected hippocampal neurons from synaptically-mediated excitotoxicity (Abood et al. 2001). Furthermore, the cannabinoid agonist CP-55, 940 protected cortical neurons from glutamatergic excitotoxicity by CB1 receptor-mediated voltage-dependent calcium channels inhibition (Hampson and Grimaldi 2001). Other synthetic cannabinoid WIN55 and 2122 administered daily (twice, 2 mg/kg) to rats increased hippocampal granule cell density and dendritic length in the CA3 pyramidal cell layer (Chan et al. 1996).

Some studies did not show any effect of marijuana in central nervous system. An MRI study found no evidence of cerebral atrophy or regional changes in tissue volumes among 18 current, frequent, adult marijuana users compared to 13 adult non-users (Block et al. 2000). A study claimed ultrastructural

changes in septum and hippocampal in rhesus monkeys by marijuana smoking (Harper et al. 1977; Heath et al. 1980), however, subsequent larger study failed to show effect of marijuana in the histopathology of monkey brain (Scallet 1991). The neuroprotective or neurotoxic effect of marijuana is potentially determined by the amount inhaled or ingested as shown in Fig. 1.

#### IV. SUMMARY

The increasing legalization of marijuana for medical and recreational use renewed the interest in its potential effect on health and therapeutic applications. Marijuana, THC, and other cannabinoid agonists all have a common problem of a narrow therapeutic window between clinical benefits and the unwanted psychic side-effects. Further elaborated studies at multiple doses for short- and long- term consumption is essential prior to conclude beneficial or detrimental effect of marijuana in the central nervous system.

#### REFERENCES RÉFÉRENCES REFERENCIAS

1. Abood ME, Rizvi G, Sallapudi N, McAllister SD. 2001. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. *Neuroscience letters* **309** (3):197-201.
2. Ameri A. 1999. The effects of cannabinoids on the brain. *Progress in neurobiology* **58**(4):315-348.
3. Bash R, Rubovitch V, Gafni M, Sarne Y. 2003. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. *Neuro-Signals* **12**(1):39-44.
4. Block RI, O'Leary DS, Ehrhardt JC, Augustinack JC, Ghoneim MM, Arndt S, Hall JA. 2000. Effects of frequent marijuana use on brain tissue volume and composition. *Neuroreport* **11**(3):491-496.
5. Calignano A, La Rana G, Giuffrida A, Piomelli D. 1998. Control of pain initiation by endogenous cannabinoids. *Nature* **394** (6690):277-281.
6. Carlini EA, Cunha JM. 1981. Hypnotic and antiepileptic effects of cannabidiol. *Journal of clinical pharmacology* **21**(8-9 Suppl):417S-427S.
7. Chan GC, Hinds TR, Impey S, Storm DR. 1998. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **18** (14):5322-5332.
8. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. 1996. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. *Fundamental and applied toxicology : official journal of the Society of Toxicology* **30** (1):109-117.
9. Court JM. 1998. Cannabis and brain function. *Journal of paediatrics and child health* **34** (1):1-5.
10. Fehr KA, Kalant H, LeBlanc AE. 1976. Residual learning deficit after heavy exposure to cannabis or alcohol in rats. *Science* **192** (4245):1249-1251.

11. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M. 1989. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. *Proceedings of the National Academy of Sciences of the United States of America* **86** (23):9584-9587.
12. Guzman M, Sanchez C, Galve-Roperh I. 2001. Control of the cell survival/death decision by cannabinoids. *Journal of molecular medicine* **78** (11):613-625.
13. Hampson AJ, Grimaldi M. 2001. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. *The European journal of neuroscience* **13** (8):1529-1536.
14. Harper JW, Heath RG, Myers WA. 1977. Effects of Cannabis sativa on ultrastructure of the synapse in monkey brain. *Journal of neuroscience research* **3**(2):87-93.
15. Heath RG, Fitzjarrell AT, Fontana CJ, Garey RE. 1980. Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys. *Biological psychiatry* **15**(5):657-690.
16. Heishman SJ, Arasteh K, Stitzer ML. 1997. Comparative effects of alcohol and marijuana on mood, memory, and performance. *Pharmacology, biochemistry, and behavior* **58**(1):93-101.
17. Heyser CJ, Hampson RE, Deadwyler SA. 1993. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. *The Journal of pharmacology and experimental therapeutics* **264** (1): 294-307.
18. Hollister LE. 1986. Health aspects of cannabis. *Pharmacological reviews* **38** (1):1-20.
19. Karler R, Turkianis SA. 1981. The cannabinoids as potential antiepileptics. *Journal of clinical pharmacology* **21**(8-9 Suppl):437S-448S.
20. Landfield PW, Cadwallader LB, Vinsant S. 1988. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. *Brain research* **443** (1-2):47-62.
21. Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM. 2000. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. *Brain research* **877** (2):407-410.
22. Lichtman AH, Martin BR. 1996. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. *Psychopharmacology* **126** (2):125-131.
23. Lukas SE, Mendelson JH, Benedikt R. 1995. Electroencephalographic correlates of marijuana-induced euphoria. *Drug and alcohol dependence* **37** (2):131-140.
24. Martin WJ, Hohmann AG, Walker JM. 1996. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **16** (20):6601-6611.
25. Mechoulam R, Panikashvili D, Shohami E. 2002. Cannabinoids and brain injury: therapeutic implications. *Trends in molecular medicine***8**(2):58-61.
26. Morris RG, Garrud P, Rawlins JN, O'Keefe J. 1982. Place navigation impaired in rats with hippocampal lesions. *Nature* **297**(5868):681-683.
27. Pope HG, Jr., Yurgelun-Todd D. 1996. The residual cognitive effects of heavy marijuana use in college students. *Jama* **275**(7):521-527.
28. Sarne Y, Asaf F, Fishbein M, Gafni M, Keren O. 2011. The dual neuroprotective-neurotoxic profile of cannabinoid drugs. *British journal of pharmacology* **163** (7):1391-1401.
29. Sarne Y, Keren O. 2004. Are cannabinoid drugs neurotoxic or neuroprotective? *Medical hypotheses* **63** (2):187-192.
30. Scallet AC. 1991. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. *Pharmacology, biochemistry, and behavior* **40** (3):671-676.
31. Schweinsburg AD, Brown SA, Tapert SF. 2008. The influence of marijuana use on neurocognitive functioning in adolescents. *Current drug abuse reviews* **1**(1):99-111.
32. Shen M, Thayer SA. 1998. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. *Molecular pharmacology* **54** (3):459-462.
33. Solowij N, Michie PT, Fox AM. 1995. Differential impairments of selective attention due to frequency and duration of cannabis use. *Biological psychiatry***37**(10):731-739.
34. Stiglick A, Kalant H. 1982. Residual effects of prolonged cannabis administration on exploration and DRL performance in rats. *Psychopharmacology* **77**(2):124-128.
35. Stiglick A, Llewellyn ME, Kalant H. 1984. Residual effects of prolonged cannabis treatment on shuttle-box avoidance in the rat. *Psychopharmacology* **84** (4):476-479.

FIGURE LEGEND

Figure 1. Marijuana dose determines beneficial or detrimental effect of marijuana consumption. Research so far indicated that low dose of marijuana has beneficial and neuroprotective response. However, higher marijuana dose stimulate psychoactive impairment as well as memory and attention deficits, potentially due to its neurotoxic effect.

FIGURE




Fig. 1

